Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn2+, Mn3+, Fe2+, Fe3+, Co2+ and Ni2+, a photochromic system which is bonded covalently to the chelate ligand and can be isomerized by irradiation, this system being bonded coordinatively to the metal ion in one configuration and not bonded to the metal ion in the other configuration.

Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Abstract: The invention relates to a method for the MRT representation of a blood vessel (A) and/or of the territory supplied by the blood vessel (A) by labeling the blood, which is guided by this blood vessel (A), by means of continuous arterial spin labeling (CASL), in a specified labeling plane (E). The position of the labeling plan (E) is varied with the provision that a specified location of the blood vessel (A) remains in the labeling plane (E). This enables, for example, a selective labeling of a blood vessel of interest to be saturated by varying the position of the labeling plane.

Abstract: The invention relates to an exonuclease 1 (EXO1) promoter polymorphism associated with exceptional life expectancy in humans. More specifically, the invention relates to the promoter region of EXO1 where the gene has been found to be mutated. Moreover, the invention relates to a gene regulation mechanism involving transcription factor E47 as a transcriptional repressor of EXO1.

Abstract: The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.

Abstract: Apparatus for minimum invasive fasciectomy, characterized by a tubular fixation element, including two detachably interconnected semitubular shells with in each case a wedge-shaped recess formed at a proximal end and at a distal end, a deflecting bar, whose length essentially corresponds to the portion between the recesses, and lifting wedges with in each case receptacles located at the lower portion thereof for the detachable connection of the lifting wedges to the deflecting bar, wherein the titling wedges can be introduced into the wedge-shaped recesses, accompanied by a sliding apart of the detachably interconnected semitubular shells.

Abstract: The present invention relates to a novel system for the trans-membrane transport including the cellular uptake/delivery of nucleic acids, substances that contain a nucleic acid component, recombinant genetic material or substances that can be attached to a nucleic acid, in biological systems. In particular, the present invention relates to a nucleic acid comprising a first nucleotide sequence having a specific signal sequence, wherein said signal sequence increases or causes the uptake of the nucleic acid into a cell, and a pharmaceutical composition containing said nucleic acid.